Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Clears GSK For ‘Quick' Trials Of H1N1 Flu Vaccine

This article was originally published in PharmAsia News

Executive Summary

India has given its okay for multinational drug maker GlaxoSmithKline to streamline usual procedures and conduct quick trials of an H1N1 flu vaccine in India. The move is expected to make the GSK vaccine available in India by the end of the year, probably as early as December. India's health ministry has ordered 10 million doses of the vaccine if the trials prove successful, a move that encouraged GSK to test the vaccine in the country. The government plans to conduct its own trials simultaneously with GSK's. (Click here for more

You may also be interested in...



Dr Reddy’s Posts Surprise Q3 Loss With NuvaRing Write-Off

Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.

Philips Delivers On Aim To Focus Exclusively On Health And Healthtech

Royal Philips is planning to sell its domestic appliance business to better focus on its strategic aims in health technology. The group made the announcement as it unveiled 2019 sales up 4.5% on a comparable basis.

Why Reviewing MDR Grace Period Interpretation Is Only Way To Stop Threat To Device Availability

With just under 120 days until the full application of the EU’s Medical Device Regulation, and fears growing of the loss of products seen as non-compliant, the EU medtech industry has identified a way of broadening the application of the “grace period.” It is a legal way of addressing the potential loss of tens of thousands of products come 26 May, says MedTech Europe’s Oliver Bisazza.

UsernamePublicRestriction

Register

SC072797

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel